Tests B7-H3 CAR T cells in children and young adults with relapsed solid tumors
Tests modified immune cells given into a vein in children with certain solid tumors.
Key facts
- Who runs it
- Stanford University
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Registry title
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 41 people, planned
- Started
- 11 Jul 2024
- Expected to end
- Jul 2029
- Type of study
- Interventional
- Treatments tested
- B7-H3CART Dose (Intravenous)
- Record updated
- 7 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults aged 2 to 30 with a solid tumor that came back or did not respond to treatment. They would get B7-H3 CAR T cells.
- Age
- 2 to 30 years old. The first three people treated must be 12 to 30 years old.
- Sex
- All sexes can join.
- Disease stage
- A confirmed solid tumor (such as neuroblastoma, soft tissue sarcoma, osteosarcoma, Ewing sarcoma or Wilms tumor) that cannot be removed by treatment and came back or grew after all standard therapies. The disease must be measurable or evaluable.
- Earlier treatment
- No limit on the number of earlier treatments. Neuroblastoma: must have had anti-GD2 antibody therapy or not tolerated it. Wait at least 2 weeks or 5 half-lives after earlier systemic therapy, and at least 3 weeks after radiation, with some exceptions.
- Biomarker or test result
- B7-H3 on the tumor cells is not required. Stored tumor tissue must be available, or the person must be willing to have a biopsy to test B7-H3.
Main reasons for not taking part
- Taking another investigational drug now
- Another cancer in the past 3 years, apart from some skin or in situ cancers
- Untreated brain metastases or uncontrolled infection
- Ongoing HIV, hepatitis B or hepatitis C infection
- Pregnant women, or need for steroids or other drugs that weaken the immune system
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Histologically confirmed malignant solid tumor (including neuroblastoma, soft tissue sarcoma, osteosarcoma, Ewing Sarcoma, and Wilms tumor) with evidence of incurable disease and tumor recurrence/progression after all available curative standard therapies; Subjects with neuroblastoma must have received or be intolerant to anti-GD2 antibody therapy; Subjects with Wilm's tumor must have received or be intolerant to ifosfamide or cyclophosphamide plus etoposide therapy or alternative salvage regimen; Subjects with embryonal rhabdomyosarcoma must have received or be intolerant to Adriamycin-based therapy; Subjects with surgically resected pulmonary osteosarcoma in first recurrence must have received surgical resection of metastatic nodules
- Subjects during dose escalation must have evaluable or measurable disease. Subjects during dose expansion must have measurable disease, except neuroblastoma which may have MIBG positive disease only
- B7-H3 positive expression on malignant cells is NOT required but archival tissue must be available, or the subject must be willing to undergo tissue biopsy for expression analysis
- Age: Must be ≥ 2 and ≤ 30 years of age; For the first three subjects treated with B7-H3CART, must be ≥ 12 and ≤ 30 years of age
- Performance Status: Patients > 16 years of age must have Karnofsky ≥ 50%. Patients ≤ 16 years of age must have Lansky scale ≥ 50%; or ECOG performance status ≤ 2
- Prior Therapy; No limit to the number of prior therapies; Prior Therapy Wash-out: At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives. Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the subject has measurable/evaluable disease outside the radiation port or the site of radiation has documented progression
- Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion); ANC ≥ 750/uL*; Platelet count ≥ 75,000/uL*; Absolute lymphocyte count ≥ 150/uL*; Adequate renal, hepatic, pulmonary and cardiac function defined as:; Creatinine within institutional norms for age(i.e. ≤ 2 mg/dL in adults or according to table below in children <18 years) OR creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min; Age (Years) Maximum \& Serum Creatinine (mg/dL):; Age (Years): ≤5 \& Maximum Serum Creatinine (mg/dL): 0.8 Age (Years): 5 < age ≤ 10 Maximum Serum Creatinine (mg/dL): 1.0 Age (Years): >10-18 Maximum Serum Creatinine (mg/dL): 1.2 Age (Years): > 18 Maximum Serum Creatinine (mg/dL): 2.0; Serum ALT/AST ≤ 2.5x ULN (unless elevated ALT/AST is associated with disease involvement of the liver, in which case this criterion will be waived and not disqualify a patient); Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an ECHO,; No clinically significant ECG findings; No clinically significant pleural effusion; Baseline oxygen saturation > 92% on room air; if cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is due to disease, based on the results of bone marrow studies
- Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
- Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen or for as long as CART cells are detectable in peripheral blood
- Must provide informed consent. For subjects <18 years old, or adults with limited decision-making capacity, their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and assent will be obtained for those > 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he/she will be asked to reconsent as an adult
Who cannot take part
- Receiving any other current investigational agents
- Presence of untreated brain metastases will be excluded. Subjects with previous CNS tumor involvement that has been treated and is stable for at least 3 months following completion of therapy are permitted. Patients who are clinically stable as evidenced by no requirements for corticosteroids, no evolving neurologic deficits, and no progression of residual brain abnormalities without specific therapy, are permitted
- Pregnant females are excluded from this study because the effects of autologous B7-H3CART on the developing human fetus are unknown and because the chemotherapy agents used in this trial (cyclophosphamide and fludarabine) are category D agents with the potential for teratogenic or abortifacient effects. Additionally, because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with cyclophosphamide/fludarabine, breastfeeding should be discontinued if the mother is treated with cyclophosphamide/fludarabine. These potential risks may also apply to other agents used in this study
- Patients who require systemic corticosteroid or other immunosuppressive therapy. (A one-week washout from systemic corticosteroid or other immunosuppressive therapy is permitted.) Use of physiologic doses of corticosteroids (up to 3 mg/m2/day prednisone equivalent) are permitted. Use of topical, ocular, intra-articular, intra-nasal, or inhaled corticosteroids are permitted
- History of other malignancy, except non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast), unless disease free for at least 3 years
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
- Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti HCV positive) as the immunosuppression contained in this study will pose unacceptable risk. A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
- Any medical condition that in the judgement of the sponsor investigator is likely to interfere with assessment of safety or efficacy of study treatment
- History of severe immediate hypersensitivity reaction to any of the agents used in this study
- Primary immunodeficiency or history of systemic autoimmune disease (e.g., Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years
- In the investigator's judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 30 years old?
Where in United States
- Stanford UniversityPalo Alto, United StatesContact: Amy LiTaking people
About the trial
What the trial wants to find out
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
The group in the trial
- LymphodepletionTreatment being tested
Fludarabine 30 mg/m2 per day IV for 4 days: 5, -4, 3, -2 Cyclophosphamide 500 mg/m2 per day IV for 3 days: -5, -4, -3 Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.
Treatment: B7-H3CART Dose (Intravenous)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Children and Young Adults With Relapsed or Refractory Solid Tumor Expressing B7-H3 Target
- Plain-language title
- Tests B7-H3 CAR T cells in children and young adults with relapsed solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06500819, who can take part
- Record updated
- 7 May 2026